Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 7/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30698534 | 0.86 | RAB9A (0.54) | MAPTRAB9ANPC1LMNASMN1; SMN2 | |
| SCHEMBL27038532 | 0.86 | RAB9A (0.54) | MAPTRAB9ANPC1LMNASMN1; SMN2 | |
| SCHEMBL8986532 | 0.86 | RAB9A (0.59) | MAPTRAB9ANPC1 | |
| SCHEMBL10264622 | 0.84 | MAPT (0.49) | MAPTPOLBCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL15434433 | 0.84 | MAPT (0.70) | MAPTPOLBRAB9ANPC1LMNA | |
| SCHEMBL30698449 | 0.83 | MAPT (0.49) | MAPTPOLBRAB9ANPC1ALDH1A1 | |
| SCHEMBL22307705 | 0.83 | MAPT (0.48) | MAPTPOLBCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL6844995 | 0.83 | MAPT (0.49) | MAPTPOLBRAB9ANPC1ALDH1A1 | |
| SCHEMBL29473072 | 0.83 | MAPT (0.48) | MAPTPOLBCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL16307606 | 0.83 | MAPT (0.47) | MAPTPOLBCYP1A2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746108-B1 | Triazolopyridine polymorph A | APM THERAPEUTICS 1, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11746108-B1 | Triazolopyridine polymorph A | APM THERAPEUTICS 1, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-9676766-B2 | Triazolopyridines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-06-13 | — | — | US | disclosed |
| US-9663510-B2 | Substituted triazolopyridines and their use as TTK inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-05-30 | — | — | US | disclosed |
| EP-3008062-B1 | PRODRUG DERIVATIVES OF SUBSTITUTED TRIAZOLOPYRIDINES | Bayer Pharma AG (DE) | 2017-04-05 | — | — | EP | disclosed |
| EP-2758396-B1 | TRIAZOLOPYRIDINE COMPOUNDS AS PDE10A INHIBITORS | HOFFMANN LA ROCHE (CH) | 2017-03-29 | — | — | EP | disclosed |
| EP-2758396-B1 | TRIAZOLOPYRIDINE COMPOUNDS AS PDE10A INHIBITORS | HOFFMANN LA ROCHE (CH) | 2017-03-29 | — | — | EP | disclosed |
| US-9586958-B2 | Prodrug derivatives of substituted triazolopyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-03-07 | — | — | US | disclosed |
| US-9555022-B2 | Substituted triazolopyridines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-01-31 | — | — | US | disclosed |
| US-20160264568-A1 | SUBSTITUTED TRIAZOLOPYRIDINES HAVING ACTIVITY AS MPS-1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-15 | — | — | US | disclosed |
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-22 | — | — | US | disclosed |
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-22 | — | — | US | disclosed |
| US-20100075965-A1 | PI3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG | 2010-03-25 | — | — | US | disclosed |
| US-20100075965-A1 | PI3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG | 2010-03-25 | — | — | US | disclosed |
| WO-2010020363-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-25 | — | — | WO | disclosed |
| WO-2009133127-A1 | FUSED BICYCLIC COMPOUNDS AND USE THEREOF AS PI3K INHIBITORS | MERCK SERONO S.A. (CH) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009068482-A1 | AMINO TRIAZOLES AS PI3K INHIBITORS | CELLZOME LIMITED (GB) | 2009-06-04 | — | — | WO | disclosed |
| WO-2009068482-A1 | AMINO TRIAZOLES AS PI3K INHIBITORS | CELLZOME LIMITED (GB) | 2009-06-04 | — | — | WO | disclosed |
| WO-2009027283-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS | MERCK SERONO S.A. (CH) | 2009-03-05 | — | — | WO | disclosed |
| WO-2007095588-A1 | PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264568-A1 | SUBSTITUTED TRIAZOLOPYRIDINES HAVING ACTIVITY AS MPS-1 INHIBITORS | CMA1, TPP1, TPSAB1 | MAPT 1979/4885POLB 1845/4885CYP1A2 624/4885 |
| US-20100075965-A1 | PI3 KINASE INHIBITORS AND METHODS OF THEIR USE | PIK3CA, PIK3CD, PIK3CB | MAPT 4111/4885POLB 1737/4885CYP1A2 4451/4885 |
| US-11746108-B1 | Triazolopyridine polymorph A | CYP3A5, CYP3A4, CYP3A43 | MAPT 535/4885POLB 1224/4885CYP1A2 8/4885 |
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | CYP3A5, ABAT, TPMT | MAPT 2724/4885POLB 2263/4885CYP1A2 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.